

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> C07K 13/00, 15/06, C12Q 1/25 C12Q 1/68, G01N 33/68	<b>A1</b>	<b>(11) International Publication Number:</b> WO 93/13129 <b>(43) International Publication Date:</b> 8 July 1993 (08.07.93)
<b>(21) International Application Number:</b> PCT/US92/11221 <b>(22) International Filing Date:</b> 24 December 1992 (24.12.92)  <b>(30) Priority data:</b> 07/814,871 24 December 1991 (24.12.91) US  <b>(71) Applicant:</b> LA JOLLA CANCER RESEARCH FOUNDATION [US/US]; 10901 North Torrey Pines Road, La Jolla, CA 92037 (US).  <b>(72) Inventors:</b> PFAHL, Magnus ; 605 North Rios Avenue, Solana Beach, CA 92075 (US). ZHANG, Xioa-Kun ; 9176F Regents Road, La Jolla, CA 92037 (US).  <b>(74) Agents:</b> PERRYMAN, David, G. et al.; Needle & Rosenberg, 133 Carnegie Way, N.W., Suite 400, Atlanta, GA 30303-1031 (US).		<b>(81) Designated States:</b> AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> NOVEL RXR-CONTAINING HETERODIMERS AND METHOD OF USE  <b>(57) Abstract</b>  This invention provides a purified heterodimer comprising an RXR and a hormone receptor. The invention also provides a method of screening ligands for their effect on the activity of an RXR-containing hormone receptor heterodimer comprising combining the heterodimer with the ligand and determining the effect on activity. Also provided is a method of amplifying the activity of a hormone receptor comprising forming a heterodimer with another hormone receptor.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

## NOVEL RXR-CONTAINING HETERODIMERS AND METHOD OF USE

This invention was made with government support under Grant  
5 Numbers DK35083 and CA50676 from the National Institutes of Health. The  
U.S. Government has certain rights in this invention.

Throughout this application various publications are referenced by  
numbers within parentheses. Full citations for these publications may be found  
10 at the end of the specification immediately preceding the claims. The  
disclosures of these publications in their entireties are hereby incorporated by  
reference into this application in order to more fully describe the state of the art  
to which this invention pertains.

15

### BACKGROUND OF THE INVENTION

Thyroid hormones as well as retinoic acid (RA) function through  
multiple nuclear receptors that belong to the steroid/thyroid hormone receptor  
superfamily (reviewed by Evans 1988; Green and Chambon, 1988). The thyroid  
20 hormone receptors (TR) are encoded by two genes (Weinberger et al., 1986;  
Jansson et al., 1983), referred to as TR $\alpha$  and TR $\beta$  from which multiple isoforms  
are generated (Benbrook and Pfahl, 1987; Nakai et al., 1988; Mitsunashi et al.,  
1988; Lazar et al., 1989; Koenig et al., 1989; Sakurai et al., 1989; Hodin et al.,  
1989). The known TR $\alpha$  subtypes are generated by alternative mRNA splicing  
25 yielding several isoforms with distinct carboxyterminal regions (Sap et al., 1986;  
Benbrook and Pfahl, 1987; Thompson et al., 1987; Mitsunashi et al., 1988; Nakai  
et al., 1988). Only one of these isoforms, TR $\alpha$ -1, is a classical ligand dependent  
transcriptional activator, while for the other splicing variants (TR $\alpha$ -2 and TR $\alpha$ -  
2V) a function as transcriptional activator could not be demonstrated  
30 (Mitsunashi et al., 1988; Lazar et al., 1989; Koenig et al., 1989; Schueler et al.,  
1990; Hermann et al., 1991). Although TR $\alpha$ -2 has been shown to exhibit weak  
repressor activity (Lazar et al., 1989; Koenig et al., 1989; Hermann et al., 1991),

the biological functions of the carboxyterminal TR $\alpha$  variants are not well understood. Two TR $\beta$  forms have been described (Weinberger et al., 1986; Hodin et al., 1989) that differ in their amino terminal regions and both are transcriptional activators. Besides their classical roles as ligand dependent enhancer proteins, TR $\alpha$ -1 and TR $\beta$ -1 function as transcriptional repressors and/or silencer proteins in the absence of ligand (Graupner et al., 1989; Damm et al., 1989; Zhang et al., 1991b; Brent et al., 1989; Graupner et al., 1991; Baniahmad et al., 1990).

10 Retinoic acid receptors (RAR) are encoded by three genes RAR $\alpha$ ,  $\beta$ , and  $\gamma$  (Petkovich et al., 1987; Giguere et al., 1987; Benbrook et al., 1988; Krust et al., 1989) from which multiple isoforms that differ in their amino terminal regions, are generated by a combination of alternative promoter usage and alternative splicing (Zelent et al., 1991; Lehmann et al., 1991; Leroy et al., 15 1991). All RAR isoforms can antagonize each other's activity (Husmann et al., 1991). A second type of RA receptor was more recently described that is only activated by high concentrations of RA and does not show significant homology in its ligand binding domain with RAR but has significant homology in its DNA binding domain (Mangelsdorf et al., 1990). It has been proposed that this 20 receptor may be activated by an unknown RA metabolite derivative (Mangelsdorf et al., 1990) and it has been designated retinoid x receptor (RXR $\alpha$ ). This receptor is highly homologous to a previously isolated orphan receptor H-2 RIIBP (Hamada et al., 1989) now usually referred to as RXR $\beta$ .

25 TRs as well as the retinoid receptors are believed to function as dimeric or multimeric proteins since they recognize and bind specifically to dimeric or multimeric response elements, that are either direct repeats or palindromic repeats. Certain response elements like the palindromic TRE, are activated by all three types of receptors, TRs, RARs, and RXRs (Umesono et 30 al., 1988; Graupner et al., 1989; Mangelsdorf et al., 1990) while other response elements are receptor specific (Hoffmann et al., 1990; Umesono et al., 1991; Näär et al., 1991). A direct repeat of the sequence TGACCT can function as a

specific response element for TRs, RARs and vitamin D receptors depending on whether the repeats are separated by 4,5 or 3 spacer nucleotides, respectively (Umesono et al., 1991). However, spacing between half-sites of response elements does not solely determine receptor specificity (Näär et al., 1991; our unpublished results).

Although a large set of data appears to suggest that TRs and RARs function as homodimers, there exists no convincing experimental evidence yet that these proteins interact with their responsive elements in vivo or in vitro specifically as homodimers. To the contrary, an increasing volume of data suggests that TRs as well as RARs require accessory nuclear proteins for efficient DNA binding (Lazar and Berrodin, 1990; Glass et al., 1990; Murray and Towle, 1989; Burnside et al., 1990; Zhang et al., 1991a), consistent with recent data from others (Forman and Samuels, 1991). Deletion of a portion of the TR $\alpha$  carboxyterminal region appears to increase DNA binding and greatly enhances dimerization and/or oligomerization, suggesting that one dimerization domain of TR $\alpha$  is located in the "DNA binding domain" (DBD). This concept is supported by structural data on the glucocorticoid (GR) (Hård et al., 1990; Luisi et al., 1991) and estrogen (ER) receptors (Schwabe et al., 1990). A second dimerization/oligomerization domain was found to be located in the "ligand binding domain" (LBD), a region that has been suggested to form a leucine zipper type structure (Forman et al., 1989). Part of the carboxyterminal region appears to inhibit the dimerization function of TR $\alpha$  such that homodimers with a palindromic TRE are not efficiently formed (Zhang et al., 1991a). Enhancement of DNA binding and the formation of a slow electrophoretic mobility complex required the presence of a protein present in nuclear extracts from a number of cell lines including F9 cells, CV-1 cells, and GC cells (Zhang et al., 1991a).

The nature of this protein could not be determined, however it is reasonable to hypothesize that this protein(s) and/or the proteins that interact with TRs and RARs, as described by others (Lazar and Berrodin, 1990; Glass et

al., 1990; Murray and Towle, 1989; Burnside et al., 1990; Rosen et al., 1991) are important components for these nuclear receptors that regulate their activity. Whether the protein(s) are members of the nuclear receptor family is not yet known, however we present data in this publication that one of the retinoid receptors, RXR $\alpha$ , strongly enhances binding of TRs and RARs to several response elements. Studies of the enhanced and upshifted TR or RAR complexes by antibodies and receptor mutants demonstrate that RXR $\alpha$  can form a heterodimer with TRs and RARs. The interaction can occur in the absence of DNA and requires both DNA and ligand binding domains of RXR $\alpha$  and the ligand binding domain of TRs or RARs. In cotransfection experiments, RXR $\alpha$  greatly enhances TR and RAR transcriptional activation activity at retinoic acid concentrations where RXR $\alpha$  itself is not significantly activated. Our data suggest that RXR $\alpha$  belongs to a novel class of nuclear receptors that we would like to term "booster receptors" (B-receptors) that at low ligand concentrations greatly enhance the activity of other receptors by heterodimer formation while, when by themselves, can not dimerize efficiently and have only low affinity for their ligands.

SUMMARY OF THE INVENTION

This invention provides a purified heterodimer comprising an RXR and a hormone receptor. The invention also provides a method of screening ligands for their effect on the activity of an RXR-containing hormone receptor heterodimer comprising combining the heterodimer with the ligand and determining the effect on activity. Also provided is a method of amplifying the activity of a hormone receptor comprising forming a heterodimer with another hormone receptor.

10

BRIEF DESCRIPTION OF THE FIGURES**Figure 1. Enhancement of TR $\alpha$  and RAR DNA binding by RXR $\alpha$** 

- (a) In vitro synthesized TR $\alpha$ , TR $\beta$ , RAR $\alpha$ , RAR $\beta$ , RAR $\gamma$  and TR $\alpha$ 2 receptor proteins were preincubated either with (+) or without (-) equal amount of in vitro synthesized RXR $\alpha$  protein at room temperature for 10 minutes. Following this preincubation, the reaction mixtures were incubated with  $^{32}$ p-labelled palindromic TRE (for sequence see Fig. 2a) and analyzed by gel retardation assay as described in Experimental Procedures. Lane 1 represents binding of unprogrammed reticulocyte lysate. The nonspecific band observed with unprogrammed reticulocyte lysate is indicated by the open triangle. Complexes migrating below or above the nonspecific band are the specific complexes of TRs in the absence of RXR $\alpha$  and the complexes formed by TRs and RARs in the presence of RXR $\alpha$ . As a control, equal amounts of TR $\alpha$  and RAR $\alpha$  proteins were also mixed and incubated with labelled TRE.
- (b) Effect of estrogen receptor. To analyze whether ER could also enhance TR $\alpha$  binding to the TRE, or whether RXR $\alpha$  would enhance ER binding to the ERE, equal amounts of in vitro synthesized ER protein were incubated with TR $\alpha$  or RXR $\alpha$  proteins and the reaction mixtures were analyzed by gel retardation using either  $^{32}$ p-labelled palindromic TRE or palindromic ERE as indicated. Control represents the binding of the unprogrammed reticulocyte to ERE. The nonspecific bands observed with unprogrammed lysate are indicated by the open triangles.
- (c) Effect of CV-1 cell extract on TR $\alpha$ DNA binding. Cell extract was prepared from CV-1 cells as described in the Experimental Procedures and the different amounts of cell extract (in microgram) were incubated either with in vitro synthesized TR $\alpha$



protein or the same volume of unprogrammed reticulocyte lysate. The reaction mixtures were then analyzed by gel retardation using  $^{32}\text{P}$ -labelled palindromic TRE.

Open triangle, solid arrow, and solid diamond indicate the nonspecific binding of the reticulocyte lysate, specific  $\text{TR}\alpha$  binding, and the upshifted  $\text{TR}\alpha$  complex, respectively.

- (d) Interaction of  $\text{RXR}\alpha$  with TR and RAR is ligand independent. The effect of  $\text{T}_3$  ( $10^{-7}$  M) or RA ( $10^{-7}$  M) on the interaction between  $\text{RXR}\alpha$  and  $\text{TR}\alpha$  or  $\text{RAR}\alpha$  was analyzed by gel retardation as described in Fig. 1a. Open triangle indicates the nonspecific binding of the unprogrammed reticulocyte lysate.

15 **Figure 2.  $\text{RXR}\alpha$  forms a complex with TRs and RARs.**

- (a) Effect of anti-Flag- $\text{RXR}\alpha$  on the slow migrating complex. In vitro synthesized Flag- $\text{RXR}\alpha$  (F- $\text{RXR}\alpha$ ) protein was incubated with in vitro synthesized  $\text{TR}\alpha$ ,  $\text{TR}\beta$ ,  $\text{RAR}\alpha$ ,  $\text{RAR}\beta$  and  $\text{RAR}\gamma$  as indicated, in the presence of anti-Flag antibody ( $\alpha$ -Flag). After incubation at room temperature for 45 minutes, the effect of antibody on slow migrating complexes was analyzed by gel retardation using  $^{32}\text{P}$ -labelled palindromic TRE as a probe. As a control, receptor mixtures were also incubated with preimmune serum (NI). The effect of anti-Flag antibody on Flag- $\text{RXR}\alpha$ ,  $\text{TR}\alpha$ ,  $\text{TR}\beta$ ,  $\text{RAR}\alpha$ ,  $\text{RAR}\beta$  and  $\text{RAR}\gamma$  was also shown. Empty triangle represents the binding of unprogrammed reticulocyte lysate (lane 1). Solid triangle represents the binding of antibody-shifted Flag- $\text{RXR}\alpha$  protein. Arrow represents the binding of antibody-shifted Flag- $\text{RXR}\alpha$ - $\text{TR}\beta$  heterodimer.
- (b) Effect of anti-Flag- $\text{TR}\alpha$  antibody on binding of the slow migrating complex. In vitro synthesized Flag- $\text{TR}\alpha$  (F- $\text{TR}\alpha$ ) protein was

incubated with in vitro synthesized RXR $\alpha$  protein in the presence or absence of anti-Flag antibody. The effect of antibody on DNA binding of the slow migrating complex was analyzed as described in figure 2a. For control, the receptor mixture was also incubated with preimmune serum (NI). The effect of anti-Flag antibody on DNA binding of Flag-RXR $\alpha$ , RXR $\alpha$ , Flag-TR $\alpha$ , and TR $\alpha$  was also analyzed. For comparison, anti-Flag antibody/Flag-RXR $\alpha$ -TR $\alpha$  interaction was run on the same gel (lanes 7-10). Open triangle represents the nonspecific binding of the unprogrammed reticulocyte lysate. Solid triangle represents the binding of the antibody-shifted RXR $\alpha$  protein. Arrow indicates the binding of antibody-upshifted Flag-TR $\alpha$  protein.

(c) Effect of anti-Flag-RAR $\gamma$  antibody on the slow migrating complex. The assay was carried out as described in figure 2b. Open triangle represents the binding of the unprogrammed reticulocyte lysate. Solid triangle indicates the binding of antibody-upshifted Flag-RXR $\alpha$  protein.

**Figure 3. Interaction of TR $\alpha$  and RXR $\alpha$  on different DNA response sequences.**

(a) Sequences of oligonucleotides used for the gel retardation assays. TRE (SEQ ID NO:9) is the perfect palindromic T3/RA response element (Glass et al., 1988; Graupner et al., 1989). TRE/OP (SEQ ID NO:10) is an oligonucleotide consisting of two TRE half-site (as indicated by the arrows) in the opposite orientation separated by 4 bp. BRARE (SEQ ID NO:11) is a RA response element present in the RAR $\beta$  promoter (Hoffmann et al., 1990). TRE/half (SEQ ID NO:12) is the half-site of TRE. ERE (SEQ ID NO:13) is the perfect palindromic ER response element (Klein-Hitpass et al., 1986). These oligonucleotides were synthesized with appropriate restriction sites at both ends as indicated by the small letters.

(b) Gel retardation analysis of RXR $\alpha$ -TR $\alpha$  interaction using different DNA response elements. Gel retardation assays were carried out essentially as described in Fig. 1a but using different response elements. (-) represents the binding of unprogrammed reticulocyte lysate. Specific binding of TR $\alpha$  to each response element is indicated by the solid arrows. Non specific bands observed with unprogrammed reticulocyte lysate are indicated by open triangles. Binding TR $\alpha$  to BRARE or RXR $\alpha$  to all response elements was not visible under the conditions used. The heterodimer formation (TR $\alpha$ /RXR $\alpha$ ) was clearly observed on the TRE, the TRE/OP and the BRARE (as indicated by the diamonds) but not on TRE/half and the ERE.

Figure 4. Ligand binding domains of TR and RAR are essential for the interaction of RXR $\alpha$ .

(a) Schematic representations of the TR $\alpha$  and c)RAR $\gamma$  deletion mutants. Numbers above the bars indicate the amino acids positions. DNA binding domain (DBD) and the ligand binding domain (LBD) are shown. A leucine-Zipper-like motif (Foreman et al., 1990) in the LBD of the TR $\alpha$  and RAR $\gamma$  containing 9 heptad repeats is indicated by the black bars. Interaction of RXR $\alpha$  with the TR $\alpha$  and d) RAR $\gamma$  deletion mutants. TR and RAR deletion mutant proteins were synthesized in vitro as described in the Experimental Procedures. Equal amounts of TR and RAR proteins and the mutant proteins were analyzed for their interaction with RXR $\alpha$  using the gel retardation assay with the palindromic TRE as described in Fig. 1a. The nonspecific binding of the unprogrammed reticulocyte lysate is indicated by the open triangles.

Figure 5. Both DNA and ligand binding domains of RXR $\alpha$  are required for interaction with TR and RAR.

(a)

Schematic representation of the RXR $\alpha$  deletion mutants. RXR $\alpha$  deletion mutants were constructed and proteins were prepared as described in the Experimental Procedures. Numbers above the bars indicate the amino acid positions. DNA binding domain (DBD) and ligand binding domain (LBD) are indicated. Single lines mark the deleted portions of the receptor. Deletion mutants RXR $\alpha$ m3, RXR $\alpha$ m4 and RXR $\alpha$ m5 are truncated cDNA clones of RXR $\alpha$  isolated from screening the human placenta  $\lambda$ gt11 cDNA library. These clones were sequenced and show identical nucleotide sequence as the wild type RXR $\alpha$ . The proteins of these cDNA clones were translated in vitro using existing Met codons for amino acid 28, 61 and 198, respectively, as determined by SDS-PAGE. The black bars indicate the untranslated portions of these three mutants.

15

Interaction of RXR $\alpha$  deletion mutants with b) TR $\alpha$  and c) RAR $\gamma$ .

20

Interaction of RXR $\alpha$  deletion mutants with TR $\alpha$  and RAR $\gamma$  was analyzed by the gel retardation assay essentially as described in Fig. 1a. The first lane represents the binding of the unprogrammed reticulocyte lysate. The nonspecific binding is indicated by the open triangles. The specific binding of TR $\alpha$  migrates faster than the nonspecific band. RAR $\gamma$  by itself shows no visible binding to TRE under the condition used. Arrows indicate the migration positions of complexes formed with RXR $\alpha$ m3 and RXR $\alpha$ m4.

25

**Figure 6. RXR $\alpha$  enhances the transcriptional activation of RAR.**

(a)

CV-1 cells were cotransfected with 100 ng of TRE<sub>2</sub>-CAT and the indicated amounts of the receptor expression vector. Cells were treated with 100 nM RA (■) or no hormone (□), and 24h later assayed for CAT activity. The mean of duplicate cultures is shown.

30

(b) The TRE-tk-CAT reporter was cotransfected into CV-1 cells with 5ng RXR $\alpha$ , or 5ng RAR $\gamma$ , or 5ng of each receptor expression vector. Cells were treated with indicated concentrations of RA and assayed for CAT activity as described in the Experimental Procedures. The activity of RXR $\alpha$  on the reporter gene in the absence of either hormone was chosen as reference value, and CAT activities were normalized accordingly. The mean of duplicate experiments is shown.

10 **Figure 7. Induction curves of RXR $\alpha$  in the presence and absence of TR $\alpha$ .**

The single palindromic TRE reporter gene (7a) or the double TRE reporter (7b) (100 ng/well) were transfected into CV-1 cells together with 5 ng RXR $\alpha$ , 100 ng reporter gene, 150 ng  $\beta$ -galactosidase plasmid, 25 ng TR $\alpha$  (or no TR $\alpha$ ) and Bluescript up to 1000 ng. Cells were grown in 24 well plates with the indicated amounts of RA and a constant amount of  $10^{-7}$  M T $_3$ . CAT activities were corrected for transfection efficiency by  $\beta$ -gal values. As control, reporter constructs were transfected alone, and CAT activities were analyzed after the same hormone treatment as described above. The activity of RXR $\alpha$  on the reporter gene in the absence of either hormone was chosen as reference value, and CAT activities were normalized accordingly. The mean values from 4 to 6 independent transfection experiments as shown. Note that CAT activities elicited by T $_3$  after cotransfection of TR $\alpha$  and RXR $\alpha$  or TR $\alpha$  alone correspond to 5-fold induction from the single TRE and 10-15-fold induction from the double TRE, respectively.

**Figure 8. Direct interaction of RXR $\alpha$  with TR or with RAR.**

30 (a) Affinity column chromatography. To analyze whether RXR $\alpha$  directly interacts with TRs and with RARs in the absence of DNA, TR $\alpha$  and RAR $\gamma$  proteins were synthesized in bacteria using

PGEX-2T expression vector (Pharmacia). Purified glutathione S-transferase-TR $\alpha$  or RAR $\gamma$  fusion proteins was also bound to a column (-). <sup>35</sup>S-labelled RXR $\alpha$  and the mutant RXR $\alpha$ m4 synthesized in vitro were then loaded on columns that contained bound glutathione transferase-TR $\alpha$  or -RAR $\gamma$  or glutathione transferase. As a control, in vitro synthesized <sup>35</sup>S-labelled ER was also loaded on a column containing bound glutathione transferase-TR $\alpha$  or -RAR $\gamma$ . After extensive washing with PBS, the bound proteins were eluted with 5 mM reduced glutathione. The elutes were concentrated using centricon 10 and analyzed on a 10% SDS-PAGE. The right panel represents in vitro translation products of RXR $\alpha$ , RXR $\alpha$ m4, and ER. Molecular weight markers (in kd) are also shown.

(b)

Immuno-coprecipitation of RXR $\alpha$  by antibody against TR or RAR. <sup>35</sup>S-labelled in vitro synthesized RXR $\alpha$  protein was incubated with partially purified bacterially expressed Flag-TR $\alpha$ , or Flag-RAR $\gamma$  (+) or similarly prepared glutathione transferase control protein (-) either in the absence or presence of cross-linker DSP as indicated on the top of the figure. After incubation, either anti-Flag antibody (F) or preimmune serum (NI) was added. The immune complexes were washed, boiled in SDS sample buffer and separated on a 10% SDS-PAGE. The labelled, in vitro synthesized RXR $\alpha$  protein is shown in the right panel together with the molecular weight marker (in kd).

DETAILED DESCRIPTION OF THE INVENTION

The present invention is based on the core discovery that an RXR can form a heterodimer with other hormone receptors to increase the activity of the receptors. This increase can be in either the hormone receptors' activity or RXR's activity. Since RXR $\alpha$  and  $\beta$  are very closely related, RXR $\beta$  has a similar activity to RXR $\alpha$ . Methods employing RXR $\beta$  utilize the same methods, conditions etc. as set forth hereinbelow for RXR $\alpha$ .

By "activity" is meant any activity which is affected by the heterodimer formation. Generally, this activity is activation or enhancement of transcription. Generally, the ligand of one or both hormone receptors of the heterodimer enhance the activity.

By "hormone receptor" is meant a receptor of the steroid/thyroid hormone receptor superfamily which forms a heterodimer with an RXR. However, oligodimers are also covered herein. Oligodimers can be tested by the methods set forth hereinbelow. Moreover, any additional receptors not tested can be tested using the methods set forth herein. Proteins having substantially the same sequence and activity of the receptors, such as "RXR", are also included in the definition of hormone receptor. Thus, minor substitutions, deletions and additions can readily be made and tested. Moreover, any receptor consisting essentially of the amino acids of the hormone receptors are included in the definition.

Additionally, since heterodimer formation can be attributed to certain portions of the hormone receptors, molecules containing only those portions are also contemplated. Also, since only certain regions of the receptor may be necessary for activity, i.e., ligand or hormone binding region, heterodimers containing only these portions of the receptors are contemplated.

The activities of the heterodimers can be applied to affect transcription in an *in vivo* system. Thus, many therapeutic applications, including enhancement or inhibition of transcription, can readily be obtained.

5           These methods can easily be adapted to use the heterodimers to screen further ligands for their effect on activity. In this way, more effective ligands can be determined. The well known methods used to screen ligands using a single receptor can readily be applied to screen using heterodimers.

10           A key discovery set forth herein is that different receptors can form heterodimers with selective enhancement or reduction in activity. Thereby specific genes can be regulated using the teachings herein.

15           The following experimental procedures and results are set forth to exemplify and not limit the invention.

### EXPERIMENTAL PROCEDURES

#### 20   Plasmid Constructions

The construction of reporter plasmids, TRE-tk-CAT and TRE<sub>2</sub>-tk-CAT has been described previously (Zhang et al., 1991b). The coding sequences of TR $\alpha$ , TR $\beta$ , RAR $\beta$ , and RAR $\gamma$  were inserted into the multiple cloning sites of the eukaryotic expression vector pECE or pBluescript (Stratagene). The  
25   construction of these plasmids has been described (Graupner et al., 1989; Zhang et al., 1991b). RAR $\alpha$  cDNA was amplified from poly(A) RNA prepared from the squamous cell carcinoma line, SCC-13, by polymerase chain reaction (PCR). The PCR products were cloned into both pECE and pBluescript. Two primers  
30   (SEQ ID NO:1 and SEQ ID NO:2) (5'-CGCAGACATGGACACCAACAT-3'; 5'-CCTCTCCACCGGCATGTCCTCG-3') were used to amplify the N-terminal half of RXR $\alpha$  cDNA from SCC-13 by PCR technique. The Smal-Sall



fragment from PCR product (530 bp) containing the DNA binding domain of the RXR $\alpha$  was used as a probe to isolate RXR $\alpha$  cDNA by screening a  $\lambda$ gt11 human placenta cDNA library (obtained from J. Millán; Millán, 1986). Several positive clones were obtained, including full length receptor and the truncated clones, RXR $\alpha$ m3, RXR $\alpha$ m4 and RXR $\alpha$ m5 which were sequenced and show identical sequences as the wild type RXR $\alpha$ . The cDNA clones were subsequently subcloned into the EcoRI site of pBluescript and pECE.

To obtain TR $\alpha$  and RAR $\gamma$  deletion mutants, existing restriction enzyme sites on receptors were used to digest receptor cDNAs. The resulting cDNA fragments were purified and cloned into pBluescript. TR $\alpha$ m1 and TR $\alpha$ m2 were generated by digesting TR $\alpha$  cDNA with XhoI (1530) and StuI (964), respectively. RAR $\gamma$ m1, RAR $\gamma$ m2, and RAR $\gamma$ m3 were generated by digesting RAR $\gamma$  cDNA with Pst I (1469), DraIII (1066), and Sac I (976), respectively (Numbers in brackets indicate the nucleotide position).

RXR $\alpha$  deletion mutants were obtained as following: RXR $\alpha$ m1 and RXR $\alpha$ m2 were generated by digesting RXR $\alpha$  cDNA with StuI (1463) and XmaIII (1231), respectively. RXR $\alpha$ m6 and RXR $\alpha$ m7 were generated by internal deletion using NcoI and BclI, respectively.

The construction of Flag-containing receptors (Flag-RXR $\alpha$ , Flag-TR $\alpha$ , and Flag-RAR $\gamma$ ) was described previously (Hermann et al., 1991; Zhang, et al., 1991a). Briefly, they were constructed by ligating a double-stranded oligonucleotide containing an ATG codon and a DNA sequence encoding Flag (SEQ ID NO:3) (Arg Tyr Lys Asp Asp Asp Asp Lys) (Hopp et al., 1988) to the N-terminus of receptors. The fusion products were then cloned into pBluescript.

#### Tissue Culture, Transient Transfection, and CAT Assay

CV-1 cells were grown in DME medium supplemented with 10% fetal calf serum (FCS). Cells were plated at  $1.0 \times 10^5$  per well in a 24 well plate

16 to 24 hours prior to transfection as described previously (Husmann et al., 1991). A modified calcium phosphate precipitation procedure was used for transient transfection and is described elsewhere (Pfahl et al., 1990). In general, 100 ng of reporter plasmid, 150 ng of  $\beta$ -galactosidase ( $\beta$ -gal) expression vector (pCH 110, Pharmacia), and variable amounts of receptor expression vector were mixed with carrier DNA (Bluescript) to 1000 ng of total DNA per plate. CAT activity was normalized for transfection efficiency by the corresponding  $\beta$ -galactosidase activity (Pfahl et al., 1990).

#### 10 Preparation of Receptor Proteins

cDNAs for RXR $\alpha$ , RAR $\alpha$ , RAR $\beta$ , RAR $\gamma$ , TR $\alpha$ , TR $\beta$ , Flag-RXR $\alpha$ , Flag-TR $\alpha$ , Flag-RAR $\gamma$  and the deletion mutants cloned into pBluescript were transcribed by using T7 and T3 RNA polymerases, and the transcripts were translated in the rabbit reticulocyte lysate system (Promega) as described (Pfahl et al., 1990; Zhang et al., 1991b). The relative amounts of the translated proteins was determined by separating the  $^{35}$ S-methionine labelled proteins on SDS-polyacrylamide gels, quantitating the amount of incorporated radioactivity and normalizing it relative to the content of methionine residues in each protein.

20 In vitro synthesized Flag-containing receptor proteins were checked for corrected sizes and antigenic specificity by immunoprecipitation with anti-Flag antibody (obtained from M. Leahy, Immunex, Seattle, Washington) followed by SDS-polyacrylamide gel electrophoresis.

25 cDNAs for RXR $\alpha$ m3, RXR $\alpha$ m4 and RXR $\alpha$ m5 cloned into pBluescript were also translated in vitro. The translation start sites of these clones used the internal ATG sequences at 28, 61 and 198 amino acid position, respectively, as determined by the SDS-PAGE analysis of the  $^{35}$ S-labelled translation products.

30 To prepare TR $\alpha$  and RAR $\gamma$  fusion proteins, Flag-TR $\alpha$  and Flag-RAR $\gamma$  cDNAs were cloned in frame into the expression vector pGcx-2T (Pharmacia). The

proteins were expressed in bacteria using the procedure provided by the manufacturer. Proteins were purified on a prepacked glutathione sepharose 4B column (Pharmacia), and checked by gel retardation assays and western blot with anti-Flag antibody.

5

### Preparation of Specific DNA Fragments

The TRE used in the experiments was a 16-bp perfect palindromic TRE (see SEQ ID NO:4) (TCAGGTCATGACCTGA) (Glass et al., 1988). An oligonucleotide flanked by a BglII adaptor sequence was synthesized (Applied Biosystems DNA Synthesizer) and purified by polyacrylamide gel electrophoresis. Oligonucleotides were annealed and were radioactively labeled using the Klenow fragment of DNA polymerase. TRE/OP is an oligonucleotide consisting of two TRE half-sites with a 4 bp spacer (SEQ ID NO:5) (GATCCTGACCTGAGATCTCAGGTCAG). TRE/half is an oligonucleotide consisting of one TRE half-site (SEQ ID NO:6) (GATCTCAGGTCA). BRARE is the direct repeat of RA response element present in RAR $\beta$  promoter (SEQ ID No:7) (AGGGTTCAGGCAAAGTTCAC). ERE is the perfect palindromic ER response element (SEQ ID NO:8) (TCAGGTCACTGTGACCTGA). These oligonucleotides are all synthesized with a BglII adaptor sequence. Labeled DNA probes were purified by gel electrophoresis and used for the gel retardation assay.

15

20

### Preparation of Cell Extracts

25

Cell extracts were prepared from CV-1 cells in a buffer containing 20 mM Hepes, pH 7.9, 0.4 M KCl, 2 mM DTT and 20% glycerol as described (Zhang et al., 1991a).

30

### Gel Retardation Assays

In vitro translated receptor protein (1 to 5  $\mu$ l depending on the translation efficiency) was incubated with the  $^{32}$ P-labeled oligonucleotides in a 20- $\mu$ l reaction mixture containing 10 mM hepes buffer, pH 7.9, 50 mM KCl, 1 mM DTT, 2.5 mM MgCl<sub>2</sub>, 10% glycerol, and 1  $\mu$ g of poly(dI-dC) at 25°C for 20 minutes. In general, relative low receptor concentration was used to obtain the clear effect of heterodimer formation. The reaction mixture was then loaded on a 5% nondenaturing polyacrylamide gel containing 0.5 x TBE (1 x TBE=0.089 M Tris-borate, 0.089 M boric acid, and 0.002 M EDTA). To analyze the effect of RXR $\alpha$  or the nuclear proteins on receptor DNA binding activity, RXR $\alpha$  or the cell extracts were preincubated with receptor protein at room temperature for 10 minutes before performing the DNA binding assay. When antibody was used, 1  $\mu$ l of the antiserum was incubated with the specific translation products at room temperature for 45 minutes before performing the experiments described above.

### Affinity column chromatography

To analyze the interaction between RXR $\alpha$  and TR $\alpha$  or and RAR $\gamma$ , purified Flag-TR $\alpha$  or Flag-RAR $\gamma$  fusion proteins were loaded on the prepacked glutathione sepharose 4B columns. For control, the vector protein (glutathione S-transferase) prepared under the same conditions was also loaded on the separate columns. The columns were washed extensively with PBS with 1% Tritonx-100.  $^{35}$ S-labelled in vitro synthesized RXR $\alpha$ , RXR $\alpha$ m4 and ER proteins were applied to the columns. Columns were then washed extensively with 3 times of 10 ml PBS. The bound protein was eluted with 50  $\mu$ M Tris pH 8 containing 50  $\mu$ M Tris pH 8 containing 5 $\mu$ M glutathione. Elutes were then concentrated by using a Centricon 10 microconcentrator, and analyzed by denaturing polyacrylamide gels.

### Immunoprecipitation

Twenty microliters of reticulocyte lysate containing in vitro translated  $^{35}\text{S}$ -labelled RXR $\alpha$  were incubated with 5  $\mu\text{l}$  (approximately 0.2  $\mu\text{g}$ ) of partially purified bacterially expressed Flag-TR $\alpha$  or Flag-RAR $\gamma$  fusion proteins or similarly prepared glutathione transferase control protein in 100  $\mu\text{l}$  buffer (containing 50 mM KCl and 10% glycerol) for 15 min. at room temperature. When cross-linker was used, we added 2  $\mu\text{l}$  of 100 mM DSP and continued the incubation at room temperature for 10 min. The reactions were then incubated with 1  $\mu\text{l}$  of anti-Flag antibody or preimmune serum for 2 hrs. on ice. Immunocomplexes were precipitated by adding 60  $\mu\text{l}$  of protein-A-sepharose slurry and mixing continuously in the cold room for 1 hr. Protein-A-sepharose was saturated in TBS buffer (Tris-buffered saline) or in RIPA buffer when cross-linker was used. The immunocomplexes were washed four times with NET-N buffer (20 mM Tris, pH 8.0, 100 mM NaCl, 1 mM DTT, 0.5% NP-40) or five times with RIPA buffer when DSP was used, and resuspended in SDS sample buffer containing 15%  $\beta$ -mercaptoethanol, boiled and resolved by SDS-polyacrylamide gel electrophoresis. The gels were fixed, dried and visualized by autoradiography.

### Results

#### RXR $\alpha$ enhances DNA binding of TRs and RARs

Previous data from us (Zhang et al., 1991a) and others (Lazar and Berroddin, 1990; Glass et al., 1990; Murray and Towle, 1989; Burnside et al., 1990; Rosen et al., 1991) suggested that TRs and RARs bind more efficiently to their response elements by binding as heterodimers or heterooligomers. Since proteins from nuclear extracts that enhance TR and/or RAR DNA binding have not been defined, we investigated the possibility that TRs can bind with increased efficiency to the palindromic TRE when complexed with other nuclear receptor proteins, in particular those that bind and activate the same or related

response elements. Using the gel retardation assay, we observed that TR $\alpha$  bound to the TRE as one major complex which migrates faster than the nonspecific band seen with unprogrammed reticulocyte lysate (Fig. 1a). This specific complex has been previously demonstrated to represent the binding of a TR $\alpha$  monomer (Zhang et al., 1991a; Forman and Samuels, 1991). When TR $\alpha$  was mixed with RXR $\alpha$ , a dramatic increase in DNA binding was seen. A prominent complex which migrated slower than the nonspecific complex was observed while the faster migrating TR $\alpha$  complex disappeared (Fig. 1a). The strong binding complex was observed at concentrations at which RXR $\alpha$  by itself did not form visible complexes with the TRE (Fig. 1d). The effect of RXR $\alpha$  was specific since no significant increase in TR $\alpha$  binding to the TRE or change of TR $\alpha$  binding pattern could be observed when it was mixed with RAR $\alpha$  (Fig. 1a) or estrogen receptor (ER) (Fig. 1b). In addition, when RXR $\alpha$  was mixed with ER and labelled ERE (Fig. 1b), no increased binding or slow electrophoretic mobility complex was seen. Interestingly, when TR $\alpha$  isoform TR $\alpha$ -2 was used, the formation of a low electrophoretic mobility complex was not observed either (Fig. 1a). These data suggest that TR $\alpha$  and RXR $\alpha$  bind as heterodimers at least by an order of magnitude more effectively to the palindromic TRE than by themselves. To investigate whether RXR $\alpha$  can also affect the binding of other nuclear receptors, RXR $\alpha$  was mixed with in vitro synthesized TR $\beta$ , RAR $\alpha$ , RAR $\beta$  and RAR $\gamma$  receptor proteins (Fig. 1a). Similar to TR $\alpha$ , the complex formed between TR $\beta$  and TRE was upshifted by RXR $\alpha$ . In the case of RAR $\alpha$ , RAR $\beta$  and RAR $\gamma$ , specific protein-DNA complexes which migrated slower than the nonspecific complex were observed only in the presence of RXR $\alpha$ , while by themselves RARs did not form detectable complexes with the TRE under the conditions used. Very similar results were also obtained with bacterially produced TR $\alpha$  and RAR $\gamma$  (data not shown). The mobility of the slow migrating complexes formed between RXR $\alpha$  and TR $\alpha$  was very similar to that formed between TR $\alpha$  and nuclear protein(s) (Fig. 1c) from CV-1 cells previously reported by us (Zhang et al., 1991a). This suggests that the protein(s) found in CV-1 cells might be RXR $\alpha$  or related protein(s). Next, we investigated the effect of T3 or RA on the interaction between RXR $\alpha$  and

TRs or RARs (Fig. 1d). We observed no clear influence of these hormones on the formation of the slow migrating complexes when TR $\alpha$  and RAR $\alpha$  were studied although T<sub>3</sub> slightly increases the migration rate of the TR $\alpha$  complex. Similar results were also obtained when TR $\beta$ , RAR $\beta$  and RAR $\gamma$  were analyzed  
5 (data not shown).

### RXR $\alpha$ forms a complex with TRs and RARs

The observation that TR is upshifted by RXR $\alpha$  but not by RAR  
10 and ER and the fact that RAR binds to the TRE strongly only in the presence of RXR $\alpha$  but not of TR, strongly suggested that RXR $\alpha$  interacts with TRs and RARs to form heterodimers or larger complexes which interact very effectively with the palindromic TRE. It is unlikely that RXR $\alpha$  catalyzed formation of TR and RAR homodimers since at high TR $\alpha$  concentrations, we have observed a  
15 TR $\alpha$  dimer complex (Zhang et al., 1991a) which comigrates with the nonspecific band of the reticulocyte lysate, and which is at a different position from the complex we observed here in the presence of RXR $\alpha$ . The slow migrating complex observed here cannot represent the binding of RXR $\alpha$  homodimers either, since the migration of the complex is different depending on which  
20 receptor is mixed with RXR $\alpha$  (Fig.1a).

To examine more directly the components of the prominent upshifted complexes, we used RXR $\alpha$ , TR $\alpha$  and RAR $\gamma$  derivatives that contained an eight-amino-acid epitope (Flag) at the amino-terminal end of these receptors  
25 (Flag-RXR $\alpha$ , Flag-TR $\alpha$  and Flag-RAR $\gamma$ , respectively) which can be recognized by a specific monoclonal antibody (Hermann et al., 1991; Zhang et al., 1991a). The behavior of these receptor derivatives was indistinguishable from that of the wild-type receptor in both transcriptional activation (Zhang et al., 1991c; data not shown) and DNA binding activity (Fig.2). When Flag-RXR $\alpha$  was incubated  
30 with anti-Flag antibody, we observed a specific complex (Fig. 2a, lanes 14 and 23; figure 2b, lane 11; figure 2c, lane 13) which was not observed when preimmune serum was used (Fig. 2b, lane 12). The complex may represent the

binding of the antibody-catalyzed Flag-RXR $\alpha$  homodimer or homooligomers. These data therefore suggest that RXR $\alpha$  by itself can not efficiently dimerize and bind to DNA. Similar antibody-induced dimerization has been observed for other receptors (Hermann et al., 1991; Zhang et al., 1991a). When Flag-RXR $\alpha$  was incubated with TRs and RARs, it behaved essentially like RXR $\alpha$ , forming prominent slow migrating complexes (Fig. 2a, lane 3, 7, 11, 16 and 20). These complexes were strongly reduced when anti-Flag antibody was added (Fig. 2a, lanes 4, 8, 12, 17 and 21). At the same time a higher molecular weight complex (indicated by the solid triangle) appeared. The reduction of the slow migrating complexes was observed when antibody was added either before or after both receptors were mixed (data not shown). The effect of antibody was specific in that the binding of these complexes was not changed when preimmune serum was used (Fig. 2a, lanes 5, 9, 13, 18 and 22), and the nonspecific binding of unprogrammed reticulocyte lysate (indicated by open triangle) was not affected by the antibody. In addition, the effect of anti-Flag antibody was specific towards Flag-RXR $\alpha$  since it did not influence the binding of TRs and RARs (Fig. 2a, lanes 24-28) and RXR $\alpha$  (Fig. 2b, lane 13). The migration of the faint higher molecular weight complex that appeared in the presence of antibody was dependent on the TR or RAR isoform used. This complex migrated at the same position as the antibody-catalyzed RXR $\alpha$  homodimer (Fig. 2a, lanes 14 and 23), suggesting that it may represent the binding of antibody-catalyzed Flag-RXR $\alpha$  homooligomer. However, the intensity of this band was much weaker than the band observed in the absence of antibody. The inhibition of the slow migrating complexes in the presence of anti-Flag antibody suggests that the antibody interacted with RXR $\alpha$ -TRs or RXR $\alpha$ -RARs complexes, resulting in the formation of larger complexes which have strongly reduced or altered affinity to DNA. When TR $\beta$  was assayed in the presence of Flag-RXR $\alpha$  and anti-Flag antibody (Fig. 2a, lane 8), we clearly observed an additional complex (indicated by arrow). This complex migrated differently from the antibody-catalyzed Flag-RXR $\alpha$  homodimer complex, and therefore may represent the binding of the antibody-upshifted Flag-RXR $\alpha$ /TR $\beta$  heterodimer. Together, these data provide strong support for the assumption that the slow migrating complexes contain



RXR $\alpha$ . More direct evidence comes from RXR $\alpha$  deletion mutant studies in which we show that the migration rate of the complexes depends on the size of the RXR $\alpha$  protein (Fig. 5).

5 We show in Figure 1 that the slow migrating complexes migrate differently depending on which TR or RAR isoform is mixed with RXR $\alpha$ , suggesting that the slow migrating complexes contain TR or RAR. To directly test this, we used Flag-TR $\alpha$  and Flag-RAR $\gamma$  (Fig. 2b and 2c). For comparison, the effect of anti-Flag antibody on Flag-RXR $\alpha$ /TR $\alpha$  and Flag-RXR $\alpha$ /RAR $\gamma$  binding is shown on the same gel (Fig. 2b, lanes 7-12; Fig. 2c, lane 8-13). The Flag-TR $\alpha$  behaved essentially as TR $\alpha$ , forming one specific complex (Fig. 2b, compare lane 1 and lane 7), which now can be upshifted by anti-Flag antibody (Fig. 2b, lane 5; indicated by arrow) but not by preimmune serum (lane 6). When Flag-TR $\alpha$  mixed with RXR $\alpha$  a slow migrating complex appeared (lane 2) 15 which is similar to the complex formed by TR $\alpha$  and Flag-RXR $\alpha$  (lane 8). The appearance of this slow migrating complex was inhibited when anti-Flag was added (lane 3). The inhibition was specific since the binding was not affected when preimmune serum was used (lane 4) and the nonspecific binding of unprogrammed reticulocyte lysate (indicated by open triangle) was not changed 20 by the antibody. In addition, the antibody did not influence the binding of wild type RXR $\alpha$  or TR $\alpha$  (lane 13 and 14). Similar to the effect of the antibody with Flag-RXR $\alpha$  and TRs or RARs (Fig. 2a), we also observed the appearance of weak slow mobility complexes when incubating antibody together with Flag-TR $\alpha$  and RXR $\alpha$ . When Flag-TR $\alpha$  was replaced with Flag-RAR $\gamma$ , similar inhibition effect of anti-Flag antibody on Flag-RAR $\gamma$ /RXR $\alpha$  binding was also seen (Fig. 25 2c). Thus, taken together, these data strongly suggest that slow migrating prominent band observed in the presence of RXR $\alpha$  contain both RXR $\alpha$  and TR or RAR.

30 A specific dimeric response element is required for heterodimer interaction

To investigate the DNA sequence requirements for effective heterodimer binding, gel retardation assays were carried out using several TRE related sequences: an inverted repeat of the TRE (TRE/OP); a TRE half-site; the  $\beta$ RARE, a retinoic acid response element (Hoffmann et al., 1990; de Thé et al., 1990); and the estrogen response element (ERE, Klein-hitpass et al, 1986) (Fig. 3a). RXR $\alpha$  alone did not bind to these DNA sequences at the concentration we used. However, when it was mixed with TR $\alpha$ , a specific slow migrating complex was observed on the TRE, TRE/OP, and the  $\beta$ RARE (Fig. 3b). Similar to the palindromic TRE, TR $\alpha$  binds to the inverted repeat of the TRE as one complex which was strongly enhanced and upshifted in the presence of RXR $\alpha$ . In case of the  $\beta$ RARE, TR $\alpha$  alone shows no visible binding but binds strongly when RXR $\alpha$  is present. Binding of TR $\alpha$  to the half-site is approximately as efficient as to the palindromic TRE in the absence of RXR $\alpha$ . However, this binding was abolished in the presence of RXR $\alpha$ , suggesting that a TR $\alpha$ /RXR $\alpha$  complex is formed but that a dimeric response element is required for heterodimer interaction. Interestingly, TR $\alpha$  also binds to the ERE, a response element identical to the palindromic TRE except for the 3 bp spacing in the center (Fig. 3a). However, when RXR $\alpha$  was added, the binding of TR $\alpha$  to ERE was abolished. The inhibition of TR $\alpha$  binding to the ERE by RXR $\alpha$  could also be due to the interaction between TR $\alpha$  and RXR $\alpha$  in solution and formation of a heterodimer which has reduced affinity or does not bind to the ERE. Together these data demonstrate that a dimeric recognition sequence must be present for effective heterodimer binding and that heterodimer binding appears to be restricted to T<sub>3</sub>/RA responsive elements. Our data suggest in addition, that RXR $\alpha$  can enhance receptor binding to quite different dimeric response elements, indicating a broad functional role for RXR $\alpha$ .

#### The carboxyterminal end of TR and RAR is necessary for interaction with RXR $\alpha$

30

To delineate regions of the TRs and RARs required for RXR $\alpha$  interaction, a number of TR $\alpha$  and RAR $\gamma$  deletion mutants were investigated

(Fig. 4a, 4c). The deletion of 8 amino acids from the TR $\alpha$  carboxyterminus did not affect TR $\alpha$ -RXR $\alpha$  interaction, however, deletion of 197 amino acids (TR $\alpha$ m2) or 243 amino acids (TR $\alpha$ m3) abolished TR $\alpha$ -RXR $\alpha$  complex formation. The TR $\alpha$ m2 and m3 mutants bound effectively to the TRE (Fig. 4b) as reported previously and are able to dimerize or oligomerize since several complexes can be observed (Zhang et al., 1991a). Similar results were also observed with RAR $\gamma$  deletion mutants (Fig. 4c, 4d). Wild type RAR $\gamma$  and the mutants do not exhibit visible binding under the conditions used. As shown before, a strong DNA binding complex was observed when RXR $\alpha$  protein was mixed with RAR $\gamma$  (Fig. 4d). However, deletion of 102 amino acid from the carboxyterminus (RAR $\gamma$ m1) completely abolished the binding of this complex. Other carboxyterminal deletion mutants behaved similarly to the RAR $\gamma$ m1 (Fig. 4c,d). Our results on the TR mutants are consistent with our observation that TR $\alpha$ -2 which has an altered carboxyterminal region (Benbrook and Pfahl, 1987) also does not form a low electrophoretic mobility complex with the TRE in the presence of RXR $\alpha$  (Fig. 1a). Mutational analysis of other receptors, including TR $\beta$ , RAR $\alpha$  and RAR $\beta$ , revealed that the carboxyterminal region of these receptors is also important for their interaction with RXR $\alpha$  (data not shown). These results therefore indicate that the carboxyterminal region TR $\alpha$  and RAR $\gamma$  is critical for interaction with RXR $\alpha$ .

#### **RXR $\alpha$ regions required for nuclear receptor interaction**

To delineate regions of RXR $\alpha$  required for nuclear receptor interaction, deletion mutants of RXR $\alpha$  were investigated (Fig. 5a) for their ability to upshift TR $\alpha$  and RAR $\gamma$  (Fig. 5b,c). Deletion of 60 (RXR $\alpha$ m1) or 75 (RXR $\alpha$ m2) amino acids from the RXR $\alpha$  carboxyterminus abolished enhancement and upshift of the TR $\alpha$  band while deletion of 28 (RXR $\alpha$ m3) or 61 (RXR $\alpha$ m4) amino acids from the amino terminus did not visibly affect interaction with TR $\alpha$ , as analyzed by the gel retardation assay (Fig. 5b). However, a comparison of the complexes observed with RXR $\alpha$ m3 and RXR $\alpha$ m4 (indicated by arrows) clearly indicates that the size of the RXR protein

determines migration of the complex. The smaller protein RXR $\alpha$ m4 forms a faster migrating complex than the larger protein (RXR $\alpha$ m3). These data therefore provide direct evidence that RXR $\alpha$  participates in the complex. In addition, we observed that the carboxyterminal but not the aminoterminal end of RXR $\alpha$  is required for interaction with TR $\alpha$ . Interestingly, an internal deletion that spanned the hinge region and the aminoterminal half of the ligand binding domain (RXR $\alpha$ m7) also abolished interaction with TR $\alpha$  (Fig. 5b). Thus both TRs as well as RXR $\alpha$  require the carboxyterminal domain for heterodimer formation. In addition, however, a truncated RXR $\alpha$  form (RXR $\alpha$ m5) in which the aminoterminal 198 amino acids were deleted (including the DNA binding domain) also failed to form a complex with TR $\alpha$ . A second mutant lacking the DNA binding domain, RXR $\alpha$ m6, was also unable to upshift TR $\alpha$ . The absence of a complex and the fact that TR $\alpha$ DNA binding was not inhibited, suggest that portions of the DNA binding region of RXR $\alpha$  are required for interaction with TR $\alpha$ . When we replaced TR $\alpha$  with RAR $\gamma$  identical results were obtained with the RXR $\alpha$  mutants (Fig. 5c). In this experiment, RXR $\alpha$ m4 also forms a complex with RAR $\gamma$  which migrates faster than the complex formed by RXR $\alpha$ m3 and RAR $\gamma$ , as indicated by arrows. Similar results were also obtained when TR $\beta$ , RAR $\alpha$  and RAR $\beta$  were used (data not shown). These data thus support the hypothesis that interaction of RXR $\alpha$  with TRs and RARs is mediated by the same structural determinants.

#### RXR $\alpha$ enhances gene activation by RARs

The ability of RXR $\alpha$  to enhance RAR and TR DNA binding could also allow enhancement of transcriptional activation of these receptors on the TRE, a known RA response element (Graupner et al., 1989; Umesono et al., 1988). When low concentrations of RXR $\alpha$  expression vector were cotransfected with RAR $\alpha$  and the TRE<sub>2</sub>-tk-CAT reporter construct, a strong enhancement of the RAR $\alpha$  activity was observed (Fig. 6a). Most interestingly, this strong enhancing activity by RXR $\alpha$  was seen at RA concentrations (10<sup>-7</sup> M) at which RXR $\alpha$  by itself was only slightly activated (Fig. 6b). The increased

activation of the reporter gene in the presence of both retinoid receptors is clearly more than additive at certain receptor concentrations as shown. For instance, when 25 ng of RAR $\alpha$  and 25 ng of RXR $\alpha$  expression vectors were used, a strong synergistic effect was observed. A very similar enhancing effect was also observed with RAR $\gamma$  (Fig. 6b). In this study, we analyzed the effect of RXR $\alpha$  on RAR $\gamma$  activity under several RA concentrations using the TRE-tk-CAT construct as reporter. At the concentrations used, neither RXR $\alpha$  by itself nor RAR $\gamma$  by itself could elicit any significant transcriptional response at RA concentrations between  $10^{-9}$  M and  $10^{-7}$  M (Fig. 6b). However, when they were transfected together, a synergistic effect (2 to 4 fold induction) was observed over this RA concentration range. Thus, the ability of RXR $\alpha$  to enhance RAR DNA binding in vitro correlates with an enhanced transcriptional activation capacity of RXR $\alpha$ -RAR complexes in vivo.

#### 15 Dual ligand requirements of the TR $\alpha$ /RXR $\alpha$ complex

The above experiment did not allow to determine whether RXR $\alpha$  itself requires ligand binding to boost transcriptional activation with RAR $\alpha$  or RAR $\gamma$ . When we cotransfected RXR $\alpha$  with TR $\alpha$ , we also observed synergism between both receptors on TRE-tk-CAT reporter constructs (Fig. 7). Some synergism was observed when only thyroid hormone ( $T_3$ ) was added, while optimal synergism required the presence of both ligands,  $T_3$  and RA. Remarkably, only low amounts of RXR $\alpha$  as well as TR $\alpha$  were required to observe a strong activation of the reporter genes.

25

To examine in detail the ligand requirements for the putative RXR $\alpha$ /TR $\alpha$  complex, we compared the RA concentrations required to activate RXR $\alpha$  alone or in combination with TR $\alpha$ . RXR $\alpha$  expression vector alone or together with TR $\alpha$  expression vector were cotransfected into CV-1 cells with reporter constructs that contain either a single (TRE-tk-CAT) or double (TRE $_2$ -tk-CAT) response element. Cells were grown in the presence of a constant amount of  $T_3$  ( $10^{-7}$  M) and various amounts of RA ( $10^{-10}$  to  $10^{-5}$  M). We

30

observed a dramatic shift of the RA responsiveness of RXR $\alpha$  in the presence of TR $\alpha$ . In cases of both the single TRE and the double TRE reporter, the RXR $\alpha$  sensitivity to RA appeared to be increased by at least 2 orders of magnitude (Fig. 7a,b). This enhanced ligand sensitivity is not due to the activation of endogenous RARs by TR $\alpha$  since no effect of CAT activity was observed when TR $\alpha$  was transfected alone (Fig. 7a,b) consistent with previous observations (Graupner et al., 1989). TR $\alpha$  alone at his low concentration did not induce the reporter gene to a high degree in the presence of T<sub>3</sub>, although an approximately 10 fold induction was observed (this is difficult to see on the scale used in Fig. 7). Thus, while RXR $\alpha$  boosts DNA binding and transcriptional activation of other receptors, by forming a complex with TR $\alpha$ , its own ligand affinity is also dramatically increased in the heterodimer complex. Our observation that RXR $\alpha$  exerts its effect on RAR $\alpha$  and RAR $\gamma$  transcriptional activity in the presence of less than 10<sup>-7</sup> M RA, suggests that complex formation between RXR $\alpha$  and RAR $\alpha$  or RAR $\gamma$  also boosts the ligand sensitivity of RXR $\alpha$  and that RA may be a natural ligand for RXR $\alpha$ .

#### Heterodimer formation occurs in the absence of DNA

An important question is whether RXR $\alpha$  can form heterodimers with the other receptors in solution or whether the heterodimeric complexes are only formed in the presence of specific DNA sequences. The ability of RXR $\alpha$  to interact with other receptors in the absence of DNA could be expected to largely enhance the efficacy of RXR $\alpha$  as a regulator of heterologous receptor activity. To investigate interaction between RXR $\alpha$  and TR or RAR in the absence of DNA, we took advantage of a unique affinity column containing glutathione coupled to sepharose to which bacterially produced receptor-glutathione transferase fusion protein binds specifically and can be eluted with free glutathione (Smith and Johnson, 1988). TR $\alpha$  or RAR $\gamma$ cDNA were cloned into the prokaryotic expression vector pGEX-2T, and expressed as TR $\alpha$ - or RAR $\gamma$ -glutathione transferase fusion proteins in bacteria. The fusion proteins were able to interact with in vitro synthesized RXR $\alpha$  as determined by gel

retardation (data not shown). We used bacterially produced TR $\alpha$ - or RAR $\gamma$ -glutathione transferase bound to the affinity resin and mixed this with in vitro synthesized  $^{35}\text{S}$  labelled receptors. After extensive washing, labelled RXR $\alpha$  could be specifically eluted with glutathione from a column that contained  
5 bound TR $\alpha$  or RAR $\gamma$  fusion protein, but RXR $\alpha$  was not retained on a column that contained only bound glutathione transferase (Fig. 8). Labelled ER was not retained on by the TR $\alpha$  or RAR $\gamma$  fusion proteins, while the mutant RXR $\alpha$ m4 that lacked 61 amino acids at the amino terminus and was able to upshift TR $\alpha$  and RAR $\gamma$ , was retained.

10

To further document the physical interaction between RXR $\alpha$  and TR or RAR, we incubated labelled RXR $\alpha$  protein, produced by cell-free translation, with or without bacterially produced Flag-TR $\alpha$  or Flag-RAR $\gamma$  proteins. Anti-Flag antibody was used to examine whether RXR $\alpha$  could be  
15 precipitated together with Flag-TR $\alpha$  or Flag-RAR $\gamma$ . As shown in Figure 8b, precipitation of Flag-TR $\alpha$  or Flag-RAR $\gamma$  resulted in a significant coprecipitation of labelled RXR $\alpha$  protein. The coprecipitation occurred even in the absence of cross-linker while it was largely enhanced when cross-linker (DSP) was used. The coprecipitation is specific since no significant amount of labelled RXR $\alpha$  was  
20 precipitated when preimmune serum was used or when RXR $\alpha$  was incubated with nonspecific control protein together with the anti-Flag antibody. The observation that RXR $\alpha$  could be coprecipitated in the absence of cross-linker and the results obtained with the affinity column strongly suggest that RXR $\alpha$  forms a stable complex with either TR or RAR in solution, and supports our  
25 interpretation of the gel retardation results shown in Figure 2.

### Discussion

#### Heterodimer formation between RXR $\alpha$ and TRs or RARs

30

Several lines of evidence are provided here for the direct interaction between RXR $\alpha$  and TRs or RARs, which result in the formation of

heterodimers which exhibit strong DNA binding to a number of T3/RA dimeric response elements. First, when RXR $\alpha$  was mixed with TR $\alpha$ , TR $\beta$ , RAR $\alpha$ , RAR $\beta$  or RAR $\gamma$ , a prominent slow migrating complex was formed which migrated at different positions depending on which TR or RAR was used (Fig. 1a). Second, using antibodies against RXR $\alpha$ , TR and RAR, we demonstrate that the binding of these slow migrating complexes can be dramatically altered by these antibodies (Fig. 2). Third, RXR $\alpha$  mutational analysis shows that the migration of these complexes depended on the size of the RXR $\alpha$  protein (Fig. 5). Finally, a study using affinity column chromatography and immunoprecipitation results demonstrate that RXR $\alpha$  can interact with TR and RAR in the absence of DNA (Fig. 8).

The enhancement of DNA binding and the characteristic upshift observed for all receptors in the presence of RXR $\alpha$  are very similar to the enhanced DNA binding and upshifts of TR $\alpha$  observed in the presence of nuclear extract from several cell lines (Fig. 1c; Zhang et al., 1991a). In addition, all TR $\alpha$  mutants investigated behave virtually identical with RXR $\alpha$  and nuclear extract protein (Fig. 4; Zhang et al., 1991a). It is therefore quite possible that RXR $\alpha$  is identical or closely related to the cellular protein previously described (Lazar and Berrodin, 1990; Murray and Towle, 1989; Burnside et al., 1990). According to its enhancing effects on TR DNA binding, the nuclear protein or proteins that enhance TR DNA binding have been termed TR auxiliary proteins - TRAP (reviewed by Rosen et al., 1991). However, if these proteins are identical with RXR $\alpha$  or a related isoform, this nomenclature is insufficient to describe their function. RXR $\alpha$ , as an example of this new receptor subclass, can not dimerize by itself efficiently but can interact with TRs or RARs to form heterodimers with strong DNA binding activity.

TR and RAR as well as RXR $\alpha$  require regions near the carboxyterminal end for interaction (Fig. 4 and Fig. 5). Interestingly, these regions are also required for TR interaction with cJun, a component of the transcription factor AP-1 that has recently been shown by us to regulate TR and



RAR activities (Zhang et al., 1991c; Yang-Yen et al., 1991). Thus, this carboxyterminal region may be viewed as a domain that can interfere with other active protein regions in possibly both cis and trans locations. The ligand binding domain of TRs and RARs was shown to possess 9 heptad repeats of hydrophobic amino acids which are structurally similar to the Leucine-Zipper dimerization domain (Forman et al., 1990). These Leucine-Zipper like motifs are thought to mediate the receptor dimerization activity by a coiled-coil  $\alpha$  helix in which a hydrophobic surface along one side of the helix could act as a dimerization interface. Similar heptad repeats are also present in the ligand binding domain of RXR $\alpha$ . The requirement of the ligand binding domain of both RXR $\alpha$  and TR or RAR for heterodimer formation implicates these Leucine-Zipper like motifs in the direct interaction between both receptors. However, RXR $\alpha$  may possess some other special structural features which are not present in TR or RAR since we could not observe clear interaction between TR and RAR when they were mixed together and were assayed under the same conditions (Fig. 1a). These special structural features may not allow RXR $\alpha$  homodimer formation, but allow RXR $\alpha$  to efficiently interact with TR and RAR. A detailed mutational analysis of RXR $\alpha$  receptor protein is therefore important in order to understand the mechanism of interaction between RXR $\alpha$  and TR or RAR. While the heptad repeats in the ligand binding domain of RAR, TR and RXR $\alpha$  may effectively interact with each other, and thereby allow receptor contact, at the same time the interaction may be extended through the dimerization domain embedded in the DNA binding region of nuclear receptors (Zhang et al., 1991a; Hård et al., 1990; Luisi et al., 1991; Schwabe et al., 1990). This is supported by our observation that the DNA binding domain of RXR $\alpha$  is also important for efficient interaction with TR or RAR (Fig. 5).

TRs and RARs are important mediators of cellular development and differentiation processes. The observation that RXR $\alpha$  can interact with TRs and RARs in the absence of DNA (Fig. 8) and the fact that the heterodimer can bind to a number of T3/RA specific response elements (Fig. 3) point to the profound role of RXR $\alpha$  in regulating these cellular processes.

Although interaction between RXR $\alpha$  and TR or RAR occurs in solution, the outcome of this interaction may depend on the sequence of the response element in particular genes. In other words, the specificity and the extent of transcriptional regulation, either positively or negatively, by receptor interactions maybe largely determined by the nature of the response elements and the receptors (and their concentrations) with which RXR $\alpha$  interacts.

### Transcriptional activity of RXR $\alpha$

Synergistic transcriptional activity of RAR and TR on the palindromic TRE was observed when they were cotransfected with RXR $\alpha$  (Fig. 6 and Fig. 7). These in vivo observations correlate very well with the strong DNA binding of heterodimers formed between RXR $\alpha$  and TR or RXR $\alpha$  and RAR. Interestingly, considerable enhancing activity of RXR $\alpha$  is observed in the absence of RA while optimal enhancement occurs already at low RA concentrations (less than  $10^{-7}$  M), whereas higher RA concentrations are required to activate RXR $\alpha$  alone (more than  $10^{-6}$  M; Fig. 6, Fig. 7; Mangelsdorf et al., 1990). Thus, while RXR $\alpha$  boosts very efficiently the activity of TRs and RARs in terms of DNA binding and transcriptional activation, its own ligand responsiveness is also boosted by the heterodimerization, i.e. mutual enhancement is occurring. This is most likely one of the major roles of RXR. We like to call this novel activity a "booster receptor" (B-receptor), in contrast to activator receptors (A-receptors). In addition to its enhancer activity, RXR forms a complex with TR $\alpha$  (and TR $\beta$ , data not shown) that appears to require two distinct hormones for full activation. This novel type of receptor complex allows direct cross-talk between two different hormonal signals at the receptor level. The palindromic TRE analyzed here is derived from the growth hormone (GH) TRE. Two years ago, Bedo et al. (1989) reported that the GH gene can be induced by RA and that the presence of T<sub>3</sub> increases the effectivity of RA by close to 3 orders of magnitude (from  $10^{-6}$  M to  $10^{-9}$  M for optimal induction). This type of in vivo observation is very similar to ours, where  $10^{-5}$  M RA are required for RXR activation while  $10^{-8}$  M is sufficient for activation of RXR $\alpha$  in

the presence of  $TR\alpha$  and  $T_3$ . A comparable synergistic effect has recently also been reported for the induction of granulocyte differentiation in leukemic cells including HL60 (Ballerini et al., 1991). Because low concentrations of  $RXR\alpha$  are sufficient for boosting  $RAR\alpha$  and  $TR\alpha$  activity, an extremely sensitive regulatory mechanism is created that can respond very efficiently to small changes in the concentrations of individual components. Our data suggest that, contrary to earlier suggestions (Mangelsdorf et al., 1990), RA is an important natural ligand for  $RXR\alpha$ ; whether other natural retinoids exist that effectively activate  $RXR\alpha$  homodimers at physiological concentrations remains to be determined.

At present it appears that more than one  $RXR$  subtype exists ( $RXR\alpha$  and  $RXR\beta$ ) that may have distinct booster specificities. Even the same  $RXR$  subtype may show considerable selectivity depending on the response element (Fig. 3), interacting receptor and receptor concentration (Fig. 6a). We have provided evidence here that the booster capacity for  $RXR\alpha$  towards  $TR\alpha$  is much higher than towards  $RAR\gamma$  (Fig. 6 and Fig. 7), and effective over a wider receptor concentration range as well (data not shown).

The subfamily of B-receptors may also include a substantial number of orphan receptors for which no specific ligands could be detected so far or other receptors that require very high ligand concentrations for efficient activation. Since  $RXR$ s appears to be encoded by more than one gene ( $RXR\alpha$  and  $RXR\beta$  whose DNA and ligand binding domains are almost identical to those of  $RXR\alpha$  is an equally good candidate. In general, the mechanisms of heterodimer formation is widely used by transcription factors, the most well known examples being AP-1 (reviewed by Karin, 1990) and the more recently described myc-max heterodimeric (Blackwood and Eisenman, 1991). Because of the obvious advantage of heterodimeric and booster receptors in many systems, our studies presented here may be the tip of the iceberg of a large field of receptor action not yet explored.

## REFERENCES

- 5 Ballerini P., Lenoble, M., Balitrand, N., Schaison, G., Najean, Y., and Chomienne, C. (1991). Stimulatory effect of thyroid hormone on RA-induced granulocytic differentiation in leukemic cells. *Leukemia* 5, 383-385.
- 10 Baniahmad, A., Steiner, C., Kohne, A.C., and Renkawitz, R. (1990). Modular structure of a chicken lysozyme silencer: involvement of an unusual thyroid hormone receptor binding site. *Cell* 61, 505-514.
- Bedo, G., Santisteban, P., and Aranda, A. (1989). Retinoic acid regulates growth hormone gene expression. *Nature* 339, 231-233.
- 15 Benbrook, D., and Pfahl, M. (1987). A novel thyroid hormone receptor encoded by a cDNA clone from a human testis library. *Science* 238, 788-791.
- Benbrook, D., Lernhardt, E., and Pfahl, M. (1988). A new retinoic acid receptor identified from a hepatocellular carcinoma. *Nature* 333, 669-672.
- 20 Blackwood, E.M., and Eisenman, R.N. (1991). Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with myc. *Nature* 251, 1211-1217.
- 25 Brent, G.A., Dunn, M.K., Harney, J.W., Gulick, T., Larsen, P.R., and Moore, D.D. (1989). Thyroid hormone aporeceptor represses T<sub>3</sub>-inducible promoters and blocks activity of the retinoic acid receptors. *New Biol* 1, 329-336.
- 30 Burnside, J., Darling, D.S., and Chin, W.W. (1990). A nuclear factor that enhances binding of thyroid hormone receptors to thyroid response elements. *J Biol Chem* 265, 2500-2504.
- Damm, K., Thompson, C.C., and Evans, R.M. (1989) Protein encoded by v-erbA functions as a thyroid-hormone receptor antagonist. *Nature* 339, 593-597.
- 35 de The, H., Vivanco-Ruiz, M.M., Tiollais, P., Stunnenberg, M., and Dejean, A. (1990). Identification of a retinoic acid response element in the retinoic acid receptor  $\beta$  gene. *Nature* 343, 177-180.
- 40 Evans, R.M. (1988). The steroid and thyroid hormone receptor family. *Science* 240, 889-895.
- 45 Forman, B.M., and Samuels, H.H. (1990). Interactions among a subfamily of nuclear hormone receptors: the regulatory zipper model. *Mol. Endocrinol.* 4, 1293-1301.

- Forman, B.M., and Samuels, H.H. (1991). p EXPRESS: a family of novel expression vectors containing a single transcription unit that is active in vitro, in prokaryotes and in eukaryotes. (in press).
- 5 Forman, B.M., Yang, C-r., Au, M., Casanova, J., Ghysdael, J., and Samuels, H.H. (1989). A domain containing leucine-zipper-like motifs between the thyroid hormone and retinoic acid receptors. *Mol Endocrinol* 3, 1610-1626.
- 10 Giguere, V., Ong, E.S., Seigi, P., and Evans, R.M. (1987). Identification of a receptor for the morphogen retinoic acid. *Nature*, 330, 624-629.
- 15 Glass, C.K., Holloway, J.M., Devary, O.V., and Rosenfeld, M.G. (1988). The thyroid hormone receptor binds with opposite transcriptional effects to a common sequence motif in thyroid hormone and estrogen response elements. *Cell* 54, 313-323.
- 20 Glass, C.K., Devary, O.V., and Rosenfeld, M.G. (1990). Multiple cell type-specific proteins differentially regulate target sequence recognition by the  $\alpha$  retinoic acid receptor *Cell* 63, 729-738.
- 20 Graupner, G., Wills, K.N., Tzukerman, M., Zhang, X-K., and Pfahl, M. (1989). Dual regulatory role for thyroid-hormone receptors allows control of retinoic-acid receptor activity. *Nature* 340, 653-656.
- 25 Graupner, G., Zhang X-k., Tzukerman, M., Wills, K., Hermann, T., and Pfahl, M. (1991). Thyroid hormone receptors repress estrogen receptor activation of a TRE. *Mol. Endocrinol.* 5, 365-372.
- 30 Green, S., and Chambon, P. (1988). Nuclear receptors enhance our understanding of transcription regulation. *Trends Genet* 4, 309-314.
- 35 Hamada, K., Gleason, S.L., Levi, B-Z., Hirschfeld, S., Appella, E., and Ozato, K. (1989). H-2RIIBP, a member of the nuclear hormone receptor superfamily that binds to both the regulatory element of major histocompatibility class I genes and the estrogen response element. *Proc. Natl. Acad. Sci., USA* 86, 8289-8293.
- 40 Härd, T., Kellenbach, E., Boelens, R., Maler, B.A., Dahlman, K., Freeman, L.P., Carlstedt-Duke, J., Yamamoto, K.R., Gustafsson, J-Å., and Kaptein, R. (1990). Solution structure of the glucocorticoid receptor DNA-binding domain. *Science* 249, 157-160.
- 45 Hermann, T., Zhang, X-k., Tzukerman, M., Wills, K.N., Graupner, G., and Pfahl, M. (1991). Regulatory functions of a non-ligand binding thyroid hormone receptor isoform. *Cell Regulation* 2, 565-574.
- Hodin, R.A., Lazar, M.A., Wintman, B.I., Darling, D.S., Koenig, R.J., Larsen, P.R., Moore, D., and Chin, W.W. (1989). Identification of a thyroid hormone receptor that is pituitary-specific. *Science* 244, 76-78.

- Hoffmann, B., Lehmann, J.M., Zhang, X-k., Hermann, T., Husmann, M., Graupner, G., and Pfahl, M. (1990). A retinoic acid receptor-specific element controls the retinoic acid receptor- $\beta$  promoter. *Mol. Endocrinol.* 4, 1727-1736.
- 5 Hopp, T.P., Prickett, K.S., Price, V.L., Libby, R.T., March C.J., Cerretti, D.P., Urdal, D.L., and Conlon, P.J.(1988). A short polypeptide marker sequence useful for recombinant protein identification and purification. *Bio-Technology* 6, 1204-1210.
- 10 Husmann, M., Lehmann, J., Hoffmann, B., Hermann, T., Tzukerman, M., and Pfahl, M. (1991). Antagonism between retinoic acid receptors. *Mol. Cell. Biol.* 11, 4097-4103.
- Jansson, M., Philipson, L., and Vennstrom, B. (1983). Isolation and  
15 characterization of multiple human genes homologous to the oncogenes of avian erythroblastosis virus.  
EMBO J 2, 561-565.
- Karin, M. (1990). The AP-1 complex and its role in transcriptional control by  
20 protein kinase C. *Molecular Aspects of Cellular Regulation* 6, 143-161.
- Klein-Hitpass, L., Schorpp, M., Wagner, U., and Ryffel, G.U. (1986). An  
estrogen-responsive element derived from the 5' flanking region of the *Xenopus*  
vitellogenin A2 functions in transfected human cells. *Cell* 46, 1053-1061.
- 25 Koenig, R.J., Lazar, M.A., Hodin, R.A., Brent, G.A., Larsen. P.R., Chin, W.W.,  
and Moore, D.D. (1989). Inhibition of thyroid hormone action by a non-  
hormone binding c-erbA protein generated by alternative mRNA splicing.  
*Nature* 337, 659-660.
- 30 Krust, A., Kastner, P.H., Petkovich, M., Zelent, A., and Chambon, P. (1989). A  
third human retinoic acid receptor, hRAR- $\gamma$ . *Proc. Natl. Acad. Sci. USA* 86,  
5310-5314.
- 35 Lazar, M.A., and Berrodin, T.J. (1990). Thyroid hormone receptors form  
distinct nuclear protein-dependent and independent complexes with a thyroid  
hormone response element.  
*Mol Endocrinol* 4, 1627-1635.
- 40 Lazar, M.A., Hodin, R.A., and Chin, W.W. (1989). Human carboxyl-terminal  
variant of  $\alpha$ -type c-erbA inhibits trans-activation by thyroid hormone receptors  
without binding thyroid hormone. *Proc Natl Acad Sci USA* 86, 7771-7774.
- Lehmann, J.M., Hoffmann, B., and Pfahl, M. (1991a). Genomic organization of  
45 the retinoic acid receptor gamma gene. *Nucleic Acids Research* 19, 573-578.
- Leroy, P., Krust, A., Zelent, A., Mendelsohn, C., Garnier, J-M., Kastner, P.,  
Dierich, A., and Chambon, P. (1991). Multiple isoforms of the mouse retinoic

acid receptor  $\alpha$  are generated by alternative splicing and differential induction by retinoic acid. *EMBO Journal* 10, 59-69.

- 5 Luisi, B.F., Xu, W.X., Otwinowski, Z., Freedman, L.P., Yamamoto, K.R., and Sigler, P.B. Crystallographic analysis of the interaction of glucocorticoid receptor with DNA. *Nature* 352, 497-505.
- 10 Mangelsdorf, D.J., Ong, E.S., Dyck, J.A., and Evans, R.M. (1990). Nuclear receptor that identifies a novel retinoic acid response pathway. *Nature* 345, 224-229.
- 15 Millán, J.L. (1986). Molecular cloning and sequence analysis of human placental alkaline phosphatase. *J. Biol. Chem.* 261, 3112-3115.
- 20 Mitsuhashi, T., Tennyson, G.E., and Nikodem, V.M. (1988). Alternative splicing generates messages encoding rat c-erbA proteins that do not bind thyroid hormone. *Proc Natl Acad Sci USA* 85, 5804-5808.
- 25 Murray, M.B., and Towle, H.C. (1989). Identification of nuclear factors that enhance binding of the thyroid hormone receptor to a thyroid hormone response element. *Mol Endocrinol* 3, 1434-1442.
- 30 Näär, A.M., Boutin, J-M., Lipkin, S.M., Yu, V.C., Holloway, J.M., Glass, C.K., and Rosenfeld, M.G. (1991). The orientation and spacing of core DNA-binding motifs dictate selective transcriptional responses to three nuclear receptors. *Cell* 65, 1267-1279.
- 35 Nakai, A., Sakurai, A., Bell, G.I., and DeGroot, L.J. (1988a). Characterization of a third human thyroid hormone receptor co-expressed with other thyroid hormone receptors in several tissues. *Mol Endo* 2, 1087-1092.
- 40 Petkovich, M., Brand, N.J., Krust, A., and Chambon, P. (1987). A human retinoic acid receptor which belongs to the family of nuclear receptors. *Nature* 330, 444-540.
- 45 Pfahl, M. and Benbrook, D. (1987). Nucleotide sequence of cDNA encoding a novel thyroid hormone receptor. *Nucl. Acids. Res.* 15, 9613.
- 40 Pfahl, M., Tzukerman, M., Zhang, X-k., Lehmann, J.M., Hermann, T., Wills, K.N., and Graupner, G. (1990). Rapid procedures for nuclear retinoic acid receptor cloning and their analysis. *Methods Enzymol.* 18, 256-270.
- 45 Rosen, E.D., O'Donnell, A.L., and Koenig, R.J. (1991). Protein-protein interactions involving erbA superfamily receptors: through the TRAP door. *Mol Cell Endocrinol* 78, C83-C88.

- Sakurai, A., Nakai, A., and DeGroot, L.J. (1989a). Expression of three forms of thyroid hormone receptor in human tissues. *Mol Endocrinol* 3, 392-399.
- 5 Sap, J., Muñoz, A., Damm, K., Goldberg, Y., Ghysdael, J., Leutz, A., Beug, H., and Vennstrom, B. (1986). The c-erb-A protein is a high-affinity receptor for thyroid hormone. *Nature* 324, 635-640.
- 10 Schueler, P.A., Schwartz, H.L., Strait, K.A., Mariash, C.N., and Oppenheimer, J.H. (1990). Binding of 3,5,3'-Triiodothyronine ( $T_3$ ) and its analogs to the in vitro translation products of c-erbA protooncogenes: differences in the affinity of the  $\alpha$ - and  $\beta$ -forms for the acetic acid analog and failure of human testis and kidney  $\alpha$ -2 products to bind  $T_3$ . *Mol. Endocrinol* 4, 227-234.
- 15 Schwabe, J.W.R., Neuhaus, D., and Rhodes, D. (1990). Solution structure of the DNA-binding domain of the estrogen receptor. *Nature* 348, 458-461.
- 20 Smith, D.B., and Johnson, K.S. (1988). Single-step purification of polypeptides expressed in *Escherichia coli* as fusions with glutathione S-transferase. *Gene* 67, 31-40.
- Thompson, C.C., Weinberger, C., Lebo, R., and Evans, R.M. (1987). Identification of a novel thyroid hormone receptor expressed in the mammalian central nervous system. *Science* 237, 1610-1613.
- 25 Umesono, K., Giguere, V., Glass, C.K., Rosenfeld, M.G., and Evans, R.M. (1988). Retinoic acid and thyroid hormone induce gene expression through a common responsive element. *Nature* 336, 262-265.
- 30 Umesono, K., Murakami, K.K., Thompson, C.C., and Evans, R.M. (1991). Direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin  $D_3$  receptors. *Cell* 65, 1255-1266.
- Weinberger, C., Thompson, C.C., Ong, E.S., Lebo, R., Gruol, D.J., and Evans, R.M. (1986). The c-erb-A gene encodes a thyroid hormone receptor. *Nature* 35 324, 641-646.
- 40 Yang-Yen, H.F., Zhang, X-k., Graupner, G., Tzukerman, M., Sakamoto, B., Karin, M., and Pfahl, M. (1991). Antagonism between retinoic acid receptors and AP-1: implications for tumor promotion and inflammation. *New Biol.* (in press).
- 45 Zelent, A., Mendelsohn, C., Kastner, P., Krust, A., Garnier, J-M., Ruffenach, F., Leroy, P., and Chambon, P. (1991). Differentially expressed isoforms of the mouse retinoic acid receptor  $\beta$  are generated by usage of two promoters and alternative splicing. *EMBO Journal* 10, 71-81.



- Zhang, X-k., Tram, P., and Pfahl, M. (1991a) DNA binding and dimerization determinants for TR $\alpha$  and its interaction with a nuclear protein. (accepted for publication Mol. Endocrinol.).
- 5 Zhang, X-K., Wills, K.N., Graupner, G., Tzukerman, M., Hermann, T., and Pfahl, M. (1991b). Ligand-binding domain of thyroid hormone receptors modulates DNA binding and determines their bifunctional roles. New Biol 3, 1-14.
- 10 Zhang, X-k., Wills, K.N., Hermann, T., Husmann, M., and Pfahl, M. (1991c). A novel pathway for thyroid hormone receptor action through interaction with JUN and FOS oncogene activities. Mol. Cell. Biol. (in press).

15

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

20

(i) APPLICANT: Pfhal, Magnus  
Zhang, Xiao-kun

25

(ii) TITLE OF INVENTION: Novel RXR-Containing Heterodimers and Method of Use

(iii) NUMBER OF SEQUENCES: 13

30

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: NEEDLE & ROSENBERG  
(B) STREET: 133 Carnegie Way, NW Ste 400  
(C) CITY: Atlanta  
(D) STATE: Georgia  
(E) COUNTRY: USA  
(F) ZIP: 30303

35

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

40

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: US 07/814,871  
(B) FILING DATE: 24-DEC-1991  
(C) CLASSIFICATION:

45

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Perryman, David G.  
(B) REGISTRATION NUMBER: 33,438  
(C) REFERENCE/DOCKET NUMBER: 1212.006

50

(ix) TELECOMMUNICATION INFORMATION:

40

(A) TELEPHONE: 404-688-0770  
(B) TELEFAX: 404-688-9880

## 5 (2) INFORMATION FOR SEQ ID NO:1:

## (i) SEQUENCE CHARACTERISTICS:

10 (A) LENGTH: 22 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA (genomic)

15

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CGCAGACATG GACACCAAAC AT

22

20

## (2) INFORMATION FOR SEQ ID NO:2:

## (i) SEQUENCE CHARACTERISTICS:

25 (A) LENGTH: 22 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA (genomic)

30

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

35 CCTCTCCACC GGCATGTCCT CG

22

## (2) INFORMATION FOR SEQ ID NO:3:

## (i) SEQUENCE CHARACTERISTICS:

40 (A) LENGTH: 8 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: peptide

45

## (v) FRAGMENT TYPE: internal

## 50 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Arg Tyr Lys Asp Asp Asp Lys  
1 5

## 55 (2) INFORMATION FOR SEQ ID NO:4:

41

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 16 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:  
TCAGGTCATG ACCTGA

16

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 26 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:  
GATCCTGACC TGAGATCTCA GGTCAG

26

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 12 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

GATCTCAGGT CA

12

(2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 20 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

5 AGGGTTCAGG CAAAGTTCAC

20

## (2) INFORMATION FOR SEQ ID NO:8:

## (i) SEQUENCE CHARACTERISTICS:

- 10 (A) LENGTH: 19 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear

15 (ii) MOLECULE TYPE: DNA (genomic)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

20 TCAGGTCACCT GTGACCTGA

19

## (2) INFORMATION FOR SEQ ID NO:9:

## (i) SEQUENCE CHARACTERISTICS:

- 25 (A) LENGTH: 24 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: DNA (genomic)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

35 GATCTCAGGT CATGACCTGA GATC

24

## (2) INFORMATION FOR SEQ ID NO:10:

## (i) SEQUENCE CHARACTERISTICS:

- 40 (A) LENGTH: 30 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear

45 (ii) MOLECULE TYPE: DNA (genomic)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

50 GATCCTGACC TGAGATCTCA GGTCAGGATC

30

55 (2) INFORMATION FOR SEQ ID NO:11:

43

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 28 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear

5

(ii) MOLECULE TYPE: DNA (genomic)

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

GATCAGGGTT CAGGCAAAGT TCACGATC

28

15 (2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 16 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear

20

(ii) MOLECULE TYPE: DNA (genomic)

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

GATCTCAGGT CAGATC

16

30

(2) INFORMATION FOR SEQ ID NO:13:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 27 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear

35

(ii) MOLECULE TYPE: DNA (genomic)

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

45 GATCTCAGGT CACTGTGACC TGAGATC

27

What is claimed is:

1. A purified heterodimer comprising an RXR and a hormone receptor.
- 5 2. The heterodimer of claim 1, wherein the RXR is RXR $\alpha$ .
3. The heterodimer of claim 1, wherein the hormone receptor is a thyroid hormone receptor.
- 10 4. The heterodimer of claim 3, wherein the thyroid hormone receptor is TR $\alpha$ .
5. The heterodimer of claim 1, wherein the hormone receptor is an retinoic acid receptor.
- 15 6. The heterodimer of claim 5, wherein the retinoic acid receptor is RAR $\alpha$ .
7. The heterodimer of claim 1, further bound to a ligand.
8. The heterodimer of claim 7, wherein the ligand is retinoic acid.
- 20 9. The heterodimer of claim 7, wherein the ligand is thyroid hormone.
10. The heterodimer of claim 7, further bound to an additional hormone receptor.
- 25 11. A method of screening ligands for their effect on the activity of an RXR-containing hormone receptor heterodimer comprising combining the heterodimer with the ligand and determining the effect on activity.
- 30 12. The method of claim 11, wherein the activity is transcriptional activation.

13. A method of determining the activity of an orphan receptor comprising forming a heterodimer between the orphan receptor and another hormone receptor and determining the activity of the heterodimer.
- 5 14. The method of claim 13, wherein the hormone receptor is an RXR.
15. A method of amplifying the activity of a hormone receptor comprising forming a heterodimer with another hormone receptor.
- 10 16. The method of claim 15, wherein one of the hormone receptors is an RXR.
17. The method of claim 16, wherein the other receptor is an retinoic acid receptor.
- 15 18. The method of claim 17, wherein the retinoic acid receptor is RAR $\alpha$ .
19. The method of claim 16, wherein the other receptor is a thyroid hormone receptor.
- 20 20. A method of selectively enhancing the activity of a hormone receptor comprising forming a heterodimer with a selected hormone receptor.
21. The method of claim 20, wherein the selected hormone receptor is RXR $\alpha$ .
- 25 22. The method of claim 20, wherein the selected hormone receptor is RXR $\beta$ .
23. A method of enhancing RXR's responsiveness to retinoic acid comprising mixing the RXR with retinoic acid receptor or thyroid hormone receptor.

						TR $\alpha$ +RAR $\alpha$	
Receptors:	-	TR $\alpha$	TR $\beta$	RAR $\alpha$	RAR $\beta$	RAR $\gamma$	TR $\alpha$ 2
RXR $\alpha$ :	-	- +	- +	- +	- +	- +	- +




FIG. 1a






FIG. 1b

SUBSTITUTE SHEET

Extract: - 1 3 3

TR $\alpha$ : + + + -



FIG. 1c

4/22





FIG. 1d

SUBSTITUTE SHEET

Receptors:	TR $\alpha$		TR $\beta$		RAR $\alpha$		RAR $\beta$		RAR $\gamma$		TR $\alpha$		RAR $\alpha$		RAR $\beta$	
	+	-	+	-	+	-	+	-	+	-	+	-	+	-	+	-
NI:	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
$\alpha$ -Flag:	-	-	+	-	-	-	-	-	-	-	+	+	+	+	+	+
F-RXR $\alpha$ :	-	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

FIG. 2a

6/22

NI :	-	-	-	+	-	+	-	-	-	+	-	+	-	-
$\alpha$ -Flag :	-	-	+	-	+	-	-	-	+	-	+	-	+	+
F-RXR $\alpha$ :	-	-	-	-	-	-	-	+	+	+	+	+	-	-
TR $\alpha$ :	-	-	-	-	-	-	+	+	+	+	-	-	-	+
RXR $\alpha$ :	-	+	+	+	-	-	-	-	-	-	-	-	+	-
F-TR $\alpha$ :	+	+	+	+	+	+	-	-	-	-	-	-	-	-




FIG. 2b

SUBSTITUTE SHEET

7/22

NI:	-	-	-	-	+	-	-	-	-	-	+	-	-	-
$\alpha$ -Flag:	-	-	-	+	-	-	+	-	-	+	-	-	+	-
F-RXR $\alpha$ :	-	-	-	-	-	-	-	-	+	+	+	+	+	+
RAR $\gamma$ :	-	-	-	-	-	-	-	+	+	+	+	-	-	-
RXR $\alpha$ :	-	-	+	+	+	+	-	-	-	-	-	-	-	-
F-RAR $\gamma$ :	-	+	+	+	+	-	+	-	-	-	-	-	-	+




FIG. 2c

8/22




FIG. 3a




FIG. 3b



10/22




FIG. 4a

SUBSTITUTE SHEET

11/22

Receptors:	TR $\alpha$	TR $\alpha$ m1	TR $\alpha$ m2	TR $\alpha$ m3								
RXR $\alpha$ :	<table border="1"><tr><td>-</td><td>+</td></tr></table>	-	+	<table border="1"><tr><td>-</td><td>+</td></tr></table>	-	+	<table border="1"><tr><td>-</td><td>+</td></tr></table>	-	+	<table border="1"><tr><td>-</td><td>+</td></tr></table>	-	+
-	+											
-	+											
-	+											
-	+											




FIG. 4b

12/22




FIG. 4c

13/22

Receptors:

	RAR $\gamma$	RAR $\gamma$ m1	RAR $\gamma$ m2	RAR $\gamma$ m3	
RXR $\alpha$ :	$\overline{-}$ $+$	$\overline{-}$ $+$	$\overline{-}$ $+$	$\overline{-}$ $+$	$+$




FIG. 4d

SUBSTITUTE SHEET

14/22




FIG. 5a

15/22

			RXR $\alpha$	RXR $\alpha$ 1	RXR $\alpha$ 2	RXR $\alpha$ 3	RXR $\alpha$ 4	RXR $\alpha$ 5	RXR $\alpha$ 6	RXR $\alpha$ 7
RXR $\alpha$ :	-	-								
TR $\alpha$ :	-	+	+	+	+	+	+	+	+	+

▽




FIG. 5b

			RXR $\alpha$	RXR $\alpha$ m1	RXR $\alpha$ m2	RXR $\alpha$ m3	RXR $\alpha$ m4	RXR $\alpha$ m5	RXR $\alpha$ m6	RXR $\alpha$ m7
RXR $\alpha$ :	-	-	+	+	+	+	+	+	+	+
RAR $\gamma$ :	-	+	+	+	+	+	+	+	+	+

▷




FIG. 5c

SUBSTITUTE SHEET

17/22




FIG. 6a



18/22




FIG. 6b

19722




FIG. 7a




FIG. 7b






FIG. 8b

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US92/11221

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(5) : C07K 13/00, 15/06; C12Q 1/25, 1/68; G01N 33/68

US CL : 530/350, 358; 435/6, 7.6, 7.8; 436/63, 501

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/350, 358; 435/6, 7.6, 7.8; 436/63, 501

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Databases: USPTO - APS, Medline, Biosis

Terms: RXR, RAR, steroid, thyroid, retino?, receptor, hetero/dimer

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
<u>X</u> Y	Cell, Volume 67, issued 20 December 1991, V. C. Yu et al., "RXR $\beta$ : A Coregulator That Enhances Binding of Retinoic Acid, Thyroid Hormone, and Vitamin D Receptors to Their Cognate Response Elements", pages 1251-1266, especially the Abstract and the final paragraph of the Discussion, page 1263.	<u>1-3, 5-8, 11, 12, 15-18, 20, 22, 23</u> 4, 9, 10, 13, 14, 19
<u>X</u> Y	Cell, Volume 59, issued 17 November 1989, C. K. Glass et al., "Positive and Negative Regulation of Gene Transcription by a Retinoic Acid-Thyroid Hormone Receptor Heterodimer", pages 697-708, especially the Abstract and the final paragraph on page 706, first column.	<u>13, 20</u> 1-12, 14-19, 22, 23
Y	Nature, Volume 345, issued 17 May 1990, D. J. Mangelsdorf et al., "Nuclear receptor that identifies a novel retinoic acid response pathway", pages 224-229, especially the Abstract; page 224, column 2; and page 227, paragraph bridging columns.	1-23

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:		* T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
* A	document defining the general state of the art which is not considered to be part of particular relevance		
* E	earlier document published on or after the international filing date	* X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
* L	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	* Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
* O	document referring to an oral disclosure, use, exhibition or other means		
* P	document published prior to the international filing date but later than the priority date claimed	* &	document member of the same patent family

Date of the actual completion of the international search  
08 March 1993

Date of mailing of the international search report  
22 MAR 1993

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Authorized officer

DAVID L. FITZGERALD

Facsimile No. NOT APPLICABLE

Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)\*

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US92/11221

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
<u>X,P</u> Y,P	EMBO Journal, Volume 11, Number 4, issued 1992, M. S. Marks et al., "H-2RIIBP (RXR $\beta$ ) heterodimerization provides a mechanism for combinatorial diversity in the regulation of retinoic acid and thyroid hormone responsive genes", pages 1419-1435, especially the Abstract.	<u>1-9, 11, 12, 15-21, 23</u> 10, 13, 14, 22
<u>X,P</u> Y,P	Proceedings of the National Academy of Sciences of the USA, Volume 89, issued February 1992, S. A. Kliewer et al., "Retinoid X receptor-COUP-TF interactions modulate retinoic acid signaling", pages 1448-1452, especially the Abstract and the entire Discussion bridging pages 1451-1452.	<u>1, 2, 11-16, 20, 21, 23</u> 3-10, 17-19, 22
A	Molecular and Cellular Biology, Volume 11, Number 10, issued October 1991, M. A. Lazar et al., "Differential DNA Binding by Monomeric, Homodimeric, and Potentially Heteromeric Forms of the Thyroid Hormone Receptor", pages 5005-5015.	1-23
A	Cell, Volume 63, issued 16 November 1990, C. K. Glass et al., "Multiple Cell Type-Specific Proteins Differentially Regulate Target Sequence Recognition by the $\alpha$ Retinoic Acid Receptor", pages 729-738.	1-23
A	Molecular Endocrinology, Volume 5, Number 1, issued 1991, D. S. Darling et al., "3,5,3'-Triiodothyronine (T <sub>3</sub> ) Receptor-Auxiliary Protein (TRAP) Binds DNA and Forms Heterodimers with the T <sub>3</sub> Receptor", pages 73-84.	1-23

Form PCT/ISA/210 (continuation of second sheet)(July 1992)\*

1/22

Receptors:  $\text{RXR}\alpha$

	$\text{TR}\alpha$	$\text{TR}\beta$	$\text{RAR}\alpha$	$\text{RAR}\beta$	$\text{RAR}\gamma$	$\text{TR}\alpha + \text{RAR}\alpha$	$\text{TR}\alpha 2$
-	-	-	-	-	-	-	-
+	+	+	+	+	+	+	+




FIG. 10

SUBSTITUTE SHEET






FIG. 1b

SUBSTITUTE SHEET

3/22

Extract: \_ 1 3 3

TRα: + + + ~




FIG. 1c

SUBSTITUTE SHEET

4/22

Receptors:	TR $\alpha$		TR $\alpha$ + RXR $\alpha$		RAR $\alpha$		RAR $\alpha$ + RXR $\alpha$		RXR $\alpha$	
	TR $\alpha$		RXR $\alpha$		RAR $\alpha$		RXR $\alpha$		RXR $\alpha$	
T3:	-	+	-	+	-	-	-	-	-	-
RA:	-	-	-	-	-	+	-	+	-	+





FIG. 1d

SUBSTITUTE SHEET

5/22

Receptors:	TR $\alpha$		TR $\beta$		RAR $\alpha$		RAR $\beta$		TR $\alpha$		RAR $\alpha$		RAR $\beta$	
	+	-	+	-	+	-	+	-	+	-	+	-	+	-
NI:	-	-	-	-	-	-	-	-	-	-	-	-	-	-
$\alpha$ -Flag:	-	-	-	-	-	-	-	-	-	-	-	-	-	-
F-RXR $\alpha$ :	-	-	-	-	-	-	-	-	-	-	-	-	-	-



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

FIG. 20

SUBSTITUTE SHEET

Ni:	-	-	-	+	-	+	-	-	-	+	-	+	-	-
$\alpha$ -Flag:	-	-	+	-	+	-	-	-	+	-	+	-	+	+
F-RXR $\alpha$ :	-	-	-	-	-	-	-	+	+	+	+	+	-	-
TR $\alpha$ :	-	-	-	-	-	-	+	+	+	+	-	-	-	+
RXR $\alpha$ :	-	+	+	+	-	-	-	-	-	-	-	-	+	-
F-TR $\alpha$ :	+	+	+	+	+	+	-	-	-	-	-	-	-	-




FIG. 2b

SUBSTITUTE SHEET

NI:	-	-	-	-	+	-	-	-	-	-	+	-	-	-
$\alpha$ -Flag:	-	-	-	+	-	-	+	-	-	+	-	-	+	-
F-RXR $\alpha$ :	-	-	-	-	-	-	-	-	+	+	+	+	+	+
RAR $\gamma$ :	-	-	-	-	-	-	-	+	+	+	+	-	-	-
RXR $\alpha$ :	-	-	+	+	+	+	-	-	-	-	-	-	-	-
F-RAR $\gamma$ :	-	+	+	+	+	-	+	-	-	-	-	-	-	+




FIG. 2c

SUBSTITUTE SHEET

8/22




FIG. 3a




FIG. 3b



10/22

INTERACTION  
WITH RXR $\alpha$



FIG. 4a

SUBSTITUTE SHEET

11/22

Receptors:      TR $\alpha$     TR $\alpha$ m1    TR $\alpha$ m2    TR $\alpha$ m3  
RXR $\alpha$ :      

-	+
---	---

-	+
---	---

-	+
---	---

-	+
---	---




FIG. 4b

SUBSTITUTE SHEET

12/22




FIG. 4c

13/22

Receptors: RAR $\gamma$  RAR $\gamma$ m1 RAR $\gamma$ m2 RAR $\gamma$ m3  
RXR $\alpha$ : 

-	+	-	+	-	+	-	+	+
---	---	---	---	---	---	---	---	---




FIG. 4d

SUBSTITUTE SHEET

14/22




FIG. 50

15/22

			RXR $\alpha$	RXR $\alpha$ 1	RXR $\alpha$ 2	RXR $\alpha$ 3	RXR $\alpha$ 4	RXR $\alpha$ 5	RXR $\alpha$ 6	RXR $\alpha$ 7
RXR $\alpha$ :	-	-								
TR $\alpha$ :	-	+	+	+	+	+	+	+	+	+

v




FIG. 5b

SUBSTITUTE SHEET

				RXR $\alpha$	RXR $\alpha$ m1	RXR $\alpha$ m2	RXR $\alpha$ m3	RXR $\alpha$ m4	RXR $\alpha$ m5	RXR $\alpha$ m6	RXR $\alpha$ m7
RXR $\alpha$ :	-	-									
RAR $\gamma$ :	-	+	+	+	+	+	+	+	+	+	+




FIG. 5c

17/22




FIG. 6a



18/22




FIG. 6b

19/22





FIG. 7a

SUBSTITUTE SHEET

20722



21/22




FIG. 8a

SUBSTITUTE SHEET

	-DSP						+DSP						
Ab	F	NI	F	F	NI	F	F	NI	F	F	NI	F	
F-RARY				+	+	-			+	+	-		
F-TR $\alpha$	+	+	-					+	-				
RXR $\alpha$	+	+	+	+	+	+	+	+	+	+	+	+	RXR $\alpha$
													200
													97.4
													68
													43
													29

FIG. 8b